Skip to main content
Premium Trial:

Request an Annual Quote

GeneFirst Gets CE-IVD Mark for Coronavirus, Flu, RSV Combo Test Kit

NEW YORK — UK molecular diagnostics firm GeneFirst said on Tuesday that it has received CE-IVD marking for its COVID-19 Plus Detection Kit for the detection of SARS-CoV-2, influenza A/B, and respiratory syncytial virus.

The test kit, which provides results in under two hours, is PCR system-agnostic and is suitable for use with a range of instruments including Roche's LightCycler, and Thermo Fisher Scientific's Applied Biosystems 7500, according to a GeneFirst spokesperson.

The spokesperson added that the COVID-19 Plus Detection Kit is now available is Europe and Asia, and that GeneFirst expects to seek Emergency Use Authorization from the US Food and Drug Administration for the test in 2021.

GeneFirst is also leading a consortium called RAPID-COVID, funded with €2.8 million ($3.4 million) from Europe's Innovative Medicines Initiative, that is developing a diagnostic kit for the detection of SARS-CoV-2 plus 30 other common respiratory bacterial and viral pathogens, the spokesperson said. The test will be designed for point-of-care and laboratory use.

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.